Envoy Medical to Host Fireside Chat with CEO Brent Lucas and the First Acclaim(R) Cochlear Implant Patient
Rhea-AI Summary
Envoy Medical (NASDAQ: COCH) will host a fireside chat on Thursday, December 11, 2025 at 4:30 P.M. ET featuring CEO Brent Lucas and Craig Eggert, the first patient to receive the Acclaim cochlear implant.
The event includes a live question-and-answer session and will be webcast. A recording will be posted on Envoy Medical's Investor Relations website after the presentation. Investors may join the company's email distribution list by emailing Envoy@kcsa.com with COCH in the subject line.
Webcast: https://ir.envoymedical.com/news-events/ir-calendar
Positive
- None.
Negative
- None.
News Market Reaction – COCH
On the day this news was published, COCH gained 4.53%, reflecting a moderate positive market reaction. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $1M to the company's valuation, bringing the market cap to $25M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Peers show mixed moves: VVOS -4.95%, ADGM -4.58%, RBOT -2.87%, IINN +0.89%, MYO 0.00%. This points to stock-specific dynamics for COCH.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Dec 04 | Investor event | Neutral | +4.5% | Announcement of a webcast fireside chat with CEO and first Acclaim patient. |
| Dec 02 | Patent grant | Positive | -0.5% | Grant of 40th U.S. patent covering cochlear implant stimulation calibration. |
| Nov 20 | Patent grant | Positive | -1.8% | New U.S. patent for implant system with removable earplug sensor and battery. |
| Nov 18 | Clinical milestone | Positive | +17.5% | First 10 Acclaim pivotal trial patients reached six-month follow-up with no SAEs. |
| Nov 10 | Earnings update | Neutral | -0.3% | Q3 2025 financials plus debt extinguishment, trial progress, and financing update. |
Recent news showed strong positive reaction to clinical trial milestones, while patent and financial updates saw small or negative moves. Neutral informational events like today’s fireside chat have also coincided with modest gains.
Over the last month, Envoy Medical reported multiple developments around its fully implanted Acclaim cochlear implant and corporate finances. A clinical milestone update on Nov 18, 2025 with no serious adverse events for the first 10 patients drew the strongest reaction. Patent grants on Nov 20 and Dec 2 modestly pressured the stock, while Q3 2025 results on Nov 10 and today’s fireside chat announcement on Dec 4 produced relatively small price moves. The current event fits into this pattern of ongoing engagement with investors around the Acclaim program.
Market Pulse Summary
This announcement highlights an investor-focused fireside chat on December 11, 2025 at 4:30 P.M. ET, featuring Envoy Medical’s CEO and the first patient implanted with the Acclaim cochlear implant. In context, it follows recent clinical milestones, new patents, and Q3 disclosures detailing both progress and financial strain. Investors may watch how management discusses trial status, commercialization plans, and prior regulatory filings about Nasdaq listing compliance and capital structure during this webcast.
Key Terms
cochlear implant medical
AI-generated analysis. Not financial advice.
Event to Take Place December 11th at 4:30 P.M. ET
White Bear Lake, Minnesota--(Newsfile Corp. - December 4, 2025) - Envoy Medical® Inc. (NASDAQ: COCH) ("Envoy Medical" or the "Company"), a hearing health company pioneering fully implanted hearing solutions, today announced that it will host a fireside chat on Thursday, December 11, 2025, at 4:30 P.M. ET featuring a conversation between CEO Brent Lucas and Craig Eggert, the first patient to receive the Acclaim™ cochlear implant.
Event: Envoy Medical Fireside Chat
Date: Thursday, December 11, 2025
Time: 4:30 P.M. ET
Webcast Link: https://ir.envoymedical.com/news-events/ir-calendar
A question and answer session will occur at the end of the call, and a link to the recording of this presentation will be available on Envoy's Investor Relations website after the event.
To be added to the Envoy Medical email distribution list, please email Envoy@kcsa.com with COCH in the subject line.
About Envoy Medical, Inc.
Envoy Medical (NASDAQ: COCH) is a hearing health company focused on providing innovative technologies across the hearing loss spectrum. Envoy Medical has pioneered one-of-a-kind, fully implanted devices for hearing loss, including its fully implanted Esteem® active middle ear implant, commercially available in the U.S. since 2010, and the fully implanted Acclaim® cochlear implant, an investigational device. Envoy Medical is dedicated to pushing hearing technology beyond the status quo to improve access, usability, compliance, and ultimately quality of life.
About the Fully Implanted Acclaim® Cochlear Implant
We believe the fully implanted Acclaim Cochlear Implant ("Acclaim CI") is a first-of-its-kind hearing device. Envoy Medical's fully implanted technology includes a sensor designed to leverage the natural anatomy of the ear instead of a microphone to capture sound.
The Acclaim CI is designed to address severe to profound sensorineural hearing loss that is not adequately addressed by hearing aids. The Acclaim CI is expected to be indicated for adults who have been deemed adequate candidates by a qualified physician.
The Acclaim Cochlear Implant received the Breakthrough Device Designation from the U.S. Food and Drug Administration (FDA) in 2019.
CAUTION The fully implanted Acclaim Cochlear Implant is an investigational device. Limited by Federal (or United States) law to investigational use.
About the Esteem® Fully Implanted Active Middle Ear Implant (FI-AMEI)
The Esteem fully implanted active middle ear implant (FI-AMEI) is the only FDA-approved, fully implanted* hearing device for adults diagnosed with moderate to severe sensorineural hearing loss allowing for 24/7 hearing capability using the ear's natural anatomy. The Esteem FI-AMEI hearing implant is invisible and requires no externally worn components and nothing is placed in the ear canal for it to function. Unlike hearing aids, you never put it on or take it off. You can't lose it. You don't clean it. The Esteem FI-AMEI hearing implant offers true 24/7 hearing.
*Once activated, the external Esteem FI-AMEI Personal Programmer is not required for daily use.
Important safety information for the Esteem FI-AMEI can be found at: https://www.envoymedical.com/safety-information.
Additional Information and Where to Find It
Copies of the documents filed by Envoy Medical with the SEC may be obtained free of charge at the SEC's website at www.sec.gov.
Forward-Looking Statements
This press release includes "forward-looking statements" within the meaning of the "safe harbor" provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-Looking statements may be identified by the use of words such as "estimate," "plan," "project," "forecast," "intend," "will," "expect," "anticipate," "believe," "seek," "target" or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters, but the absence of these words does not mean that a statement is not forward-looking. Such statements may include, but are not limited to, statements regarding the expectations of Envoy Medical concerning the outlook for its business, productivity, plans and goals for future operations; the ability to obtain and maintain compliance with Nasdaq rules and requirements; the timing and future outcome of its FDA pivotal trial; the ability to raise capital and the amount of capital required to complete the FDA pivotal trial; the Acclaim CI being the first to market fully implanted cochlear implant; the timing and results of activations, enrollments, follow-up visits, data, and clinical trials of the Acclaim CI; and the participation or any changes or delays in participation of any subjects, institutions, or healthcare professionals in such trials; the safety, performance, and market acceptance of the Acclaim CI; the timing and results of the Acclaim CI's PMA submission to the FDA; the size of Envoy Medical's addressable market, operational performance, future market conditions or economic performance and developments in the capital and credit markets; and any information concerning possible or assumed future operations of Envoy Medical. The forward-looking statements contained in this press release reflect Envoy Medical's current views about future events and are subject to numerous known and unknown risks, uncertainties, assumptions and changes in circumstances that may cause its actual results to differ significantly from those expressed in any forward-looking statement. Envoy Medical does not guarantee that the events described will happen as described (or that they will happen at all). These forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to changes in the market price of shares of Envoy Medical's Class A Common Stock; changes in or removal of Envoy Medical's shares inclusion in any index; Envoy Medical's success in retaining or recruiting, or changes required in, its officers, key employees or directors; unpredictability in the medical device industry, the regulatory process to approve medical devices, and the clinical development process of Envoy Medical products; the ability to engage competition in the medical device industry, and the failure to introduce new products and services in a timely manner or at competitive prices to compete successfully against competitors; disruptions in relationships with Envoy Medical's suppliers, or disruptions in Envoy Medical's own production capabilities for some of the key components and materials of its products; changes in the need for capital and the availability of financing and capital to fund these needs; changes in interest rates or rates of inflation; legal, regulatory and other proceedings could be costly and time-consuming to defend; changes in applicable laws or regulations, or the application thereof on Envoy Medical; a loss of any of Envoy Medical's key intellectual property rights or failure to adequately protect intellectual property rights; the effects of catastrophic events, including war, terrorism and other international conflicts; and other risks and uncertainties set forth in the section entitled "Risk Factors" and "Cautionary Note Regarding Forward-Looking Statements" in the Annual Report on Form 10-K filed by Envoy Medical on March 31, 2025, and in other reports Envoy Medical files, with the SEC. If any of these risks materialize or Envoy Medical's assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. While forward-looking statements reflect Envoy Medical's good faith beliefs, they are not guarantees of future performance. Envoy Medical disclaims any obligation to publicly update or revise any forward-looking statement to reflect changes in underlying assumptions or factors, new information, data or methods, future events or other changes after the date of this press release, except as required by applicable law. You should not place undue reliance on any forward-looking statements, which are based only on information currently available to Envoy Medical.
Investor Contact:
Phil Carlson
KCSA Strategic Communications
O: 212.896.1233
E: Envoy@kcsa.com
Media Contact:
Anne Donohoe
KCSA Strategic Communications
O: 732-620-0033
E: Envoy@kcsa.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/276860
FAQ
When is Envoy Medical's fireside chat with CEO Brent Lucas and the first Acclaim patient (COCH)?
Who will speak at the Envoy Medical (COCH) December 11, 2025 webcast?
How can investors watch the Envoy Medical (COCH) webcast on December 11, 2025?
Will there be a Q&A and recording for the Envoy Medical (COCH) December 11 event?
How do I join Envoy Medical's (COCH) investor email list to receive event notices?
